RNA‐seq Molecular Risk Classification Refines Prognostic Stratification in Childhood B‐Cell Acute Lymphoblastic Leukemia Treated With the CCCG‐ALL‐2020 Protocol: A Real‐World Cohort Study
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70548 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Yang Zhai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology/Oncology, Children's Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, RNA-Seq, Biomarkers, Tumor. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Background
Clinical risk group and early minimal residual disease (MRD) guide therapy for childhood B‐cell acute lymphoblastic leukemia (B‐ALL) but may not capture all molecular heterogeneity. We evaluated whether RNA sequencing (RNA‐seq) molecular risk classification improved outcome prediction under Chinese Children's Cancer Group (CCCG)‐acute lymphoblastic leukemia (ALL)‐2020. Procedure This retrospective cohort included 531 children with newly diagnosed B‐ALL treated at the Children's Hospital of Soochow University from 2020 to 2025. RNA‐seq subtypes were grouped as favorable, intermediate/other, or adverse risk. The primary endpoint was standard event‐free survival (EFS). Real‐world EFS additionally counted treatment abandonment and non‐protocol discontinuation. Cox models and Harrell's C ‐index evaluated prognostic performance.
Results
Favorable, intermediate/other, and adverse molecular risk groups included 285, 152, and 94 patients, respectively. The 4‐year standard EFS and overall survival were 85.2% and 95.3%. In the integrated Cox model, compared with favorable molecular risk, intermediate/other risk (hazard ratio [HR], 3.23; 95% confidence interval [CI], 1.58–6.60; p = 0.001) and adverse risk (HR, 4.22; 95% CI, 1.94–9.17; p < 0.001) were independently associated with inferior EFS. Adding Day‐19 MRD and molecular risk group increased Harrell's C ‐index from 0.698 to 0.762. Under the real‐world EFS definition, adverse molecular risk remained associated with inferior outcomes.
Conclusions
RNA‐seq molecular risk classification added prognostic information beyond protocol‐assigned clinical risk and early MRD in CCCG‐ALL‐2020‐treated B‐ALL. These findings support prospective validation of transcriptomic risk assessment but do not establish RNA‐seq as a stand‐alone treatment‐allocation tool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology/Oncology, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.
ORCID-Profile: Yang Zhai
Zitieren
APA
Zhai, Y., Yuan, H., & Kong, L. (2026). RNA‐seq Molecular Risk Classification Refines Prognostic Stratification in Childhood B‐Cell Acute Lymphoblastic Leukemia Treated With the CCCG‐ALL‐2020 Protocol: A Real‐World Cohort Study. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70548
Vancouver
Zhai Y, Yuan H, Kong L. RNA‐seq Molecular Risk Classification Refines Prognostic Stratification in Childhood B‐Cell Acute Lymphoblastic Leukemia Treated With the CCCG‐ALL‐2020 Protocol: A Real‐World Cohort Study. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70548
BibTeX
@article{Zhai2026,
author = {Zhai, Yang and Yuan, Hao and Kong, Lingjun},
title = {RNA‐seq Molecular Risk Classification Refines Prognostic Stratification in Childhood B‐Cell Acute Lymphoblastic Leukemia Treated With the CCCG‐ALL‐2020 Protocol: A Real‐World Cohort Study},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70548}
}
EUVIMED